References

1. XIMINO [prescribing information]. Scottsdale, AZ. Journey Medical Corporation; 2020.

2. Del Rosso JQ. Weight-based Dosing and Extended-release Formulation of Minocycline Tablets: Is There Clinical Significance? J Clin Aesthet Dermatol. 2009;2(1):44-7.

3. Fleischer AB, Dinehart S, Stough D, et al. Safety and Efficacy of a New Extended Release Formulation of Minocycline. Cutis. 2006;78(suppl 4):21-31.

4. Johnson BA, Nunley JR. Use of systemic agents in the treatment of acne vulgaris. Am Fam Physician. 2000;62(8):1823-1830.

5. Overgaard AB, Højsted J, Hansen R, et al. Patients' evaluation of shape, size and colour of solid dosage forms. Pharm World Sci. 2001;23(5):185-8.

6. Well D. Acne vulgaris: A review of causes and treatment options. Nurse Pract. 2013;38(10):22-31; quiz 32.

7. Cleveland Clinic. Acne. https://my.clevelandclinic.org/health/diseases/12233-acne. Accessed May 26, 2021.

8. Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci. 2011;1241:17-32.

9. American Academy of Dermatology. Acne tips for managing. https://www.aad.org/public/diseases/acne-and-rosacea/acne. Accessed May 26, 2021.

10. US Dept of Health and Human Services. What is acne? http://www.niams.nih.gov/Health_Info/Acne/acne_ff.pdf. Updated November 2014. Accessed May 26, 2021.

11. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines for the care and management of acne vulgaris. J Am Acad Dermatol. 2016;74:945-73.